1-20 of 21
Yumi Yokoyama
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 3027: Elucidating the role of glutamine metabolism in head & neck squamous cell carcinoma

Michael Allevato, Yumi Yokoyama, Robert Wild, J. Silvio Gutkind
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 3027.
https://doi.org/10.1158/1538-7445.AM2022-3027
Published: 15 June 2022
View article titled, Abstract 3027: Elucidating the role of glutamine metabolism in head & neck squamous cell carcinoma
Journal Articles

Abstract 1572: Broad glutamine pathway inhibition by DRP-104 results in anti-tumor activity in hypermetabolic lung tumors resistant to PD-1 or osimertinib therapy

Morgan Brady, Milica Momcilovic, Chiara Montemurro, Yumi Yokoyama, Heather Christofk, Katerina Politi, Margaret Dugan, Aaron Lisberg, Robert Wild, David B. Shackelford
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1572.
https://doi.org/10.1158/1538-7445.AM2021-1572
Published: 01 July 2021
View article titled, Abstract 1572: Broad glutamine pathway inhibition by DRP-104 results in anti-tumor activity in hypermetabolic lung tumors resistant to PD-1 or osimertinib therapy
Journal Articles

Abstract 1563: DRP-104, a broad acting glutamine antagonist, synergizes with immune checkpoint blockade in vivo

Yumi Yokoyama, Robert Wild
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1563.
https://doi.org/10.1158/1538-7445.AM2021-1563
Published: 01 July 2021
View article titled, Abstract 1563: DRP-104, a broad acting glutamine antagonist, synergizes with immune checkpoint blockade <em>in vivo</em>
Journal Articles

Abstract 2339: Halting head & neck squamous cell carcinoma progression by broadly targeting glutamine metabolic pathways

Michael Allevato, Yumi Yokoyama, Robert Wild, Silvio Gutkind
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 2339.
https://doi.org/10.1158/1538-7445.AM2021-2339
Published: 01 July 2021
View article titled, Abstract 2339: Halting head &amp; neck squamous cell carcinoma progression by broadly targeting glutamine metabolic pathways
Journal Articles

Abstract 5607: Broad acting glutamine antagonism remodels the tumor microenvironment, induces distinctive immune modulation, and synergizes with immune checkpoint blockade

Yumi Yokoyama, Robert Wild
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 5607.
https://doi.org/10.1158/1538-7445.AM2020-5607
Published: 15 August 2020
View article titled, Abstract 5607: Broad acting glutamine antagonism remodels the tumor microenvironment, induces distinctive immune modulation, and synergizes with immune checkpoint blockade
Journal Articles

Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor

Yumi Yokoyama, Erin D. Lew, Ruth Seelige, Elizabeth A. Tindall, Colin Walsh, Patrick C. Fagan, Jack Y. Lee, Robin Nevarez, Joanne Oh, Kathleen D. Tucker, Marissa Chen, Amy Diliberto, Heather Vaaler, Kristen M. Smith, Amanda Albert, Gary Li, Jack D. Bui
Journal: Cancer Research
Cancer Res (2019) 79 (8): 1996–2008.
https://doi.org/10.1158/0008-5472.CAN-18-2022
Published: 15 April 2019
View article titled, Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor
Open the PDF for Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor in another window
Includes: Supplementary data
Journal Articles

Abstract 3771: Mechanistic and pharmacodynamic characterization of the immuno-oncological activity of RXDX-106, a novel TYRO3, AXL, and MER (TAM) inhibitor in clinical development

Amanda Albert, Erin D. Lew, Kristen Smith, Elizabeth A. Tindall, Yumi Yokoyama, Amy Diliberto, Heather Ely, Jack Lee, Robin Nevarez, Joanne Oh, Colin Walsh, Jason Christiansen, Gary Li, Robert Shoemaker
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 3771.
https://doi.org/10.1158/1538-7445.AM2018-3771
Published: 01 July 2018
View article titled, Abstract 3771: Mechanistic and pharmacodynamic characterization of the immuno-oncological activity of RXDX-106, a novel TYRO3, AXL, and MER (TAM) inhibitor in clinical development
Journal Articles

Abstract 3767: Imprime PGG, a soluble yeast b-glucan PAMP, enhancement of anti-tumor responses in combination with tumor targeting antibody is highly dependent on NK cell killing

Kathryn A. Fraser, Takashi Kangas, Ross B. Fulton, Steven M. Leonardo, Ben Harrison, Yumi Yokoyama, Nandita Bose, Jeremy R. Graff, Mark Uhlik, Keith B. Gorden
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 3767.
https://doi.org/10.1158/1538-7445.AM2018-3767
Published: 01 July 2018
View article titled, Abstract 3767: Imprime PGG, a soluble yeast b-glucan PAMP, enhancement of anti-tumor responses in combination with tumor targeting antibody is highly dependent on NK cell killing
Journal Articles

Abstract 335: In situ protein complexes as a measure of AXL signaling and inhibitor response in cell line models of lung cancer

Anurima Majumder, Yun Bai, Fumi Kinose, Erin D. Lew, Yumi Yokoyama, Danielle Murphy, Gary Li, Eric B. Haura
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 335.
https://doi.org/10.1158/1538-7445.AM2017-335
Published: 01 July 2017
View article titled, Abstract 335: <em>In situ</em> protein complexes as a measure of AXL signaling and inhibitor response in cell line models of lung cancer
Journal Articles

Abstract 4698: Immuno-oncological efficacy of RXDX-106, a novel, selective and potent small molecule TAM (TYRO3, AXL, MER) inhibitor

Yumi Yokoyama, Erin D. Lew, Ruth Seelige, Colin Walsh, Maria Barrera, Elizabeth Tindall, Joanne Oh, Heather Ely, Amy Diliberto, Amanda Albert, Jack Bui, Gary Li
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 4698.
https://doi.org/10.1158/1538-7445.AM2017-4698
Published: 01 July 2017
View article titled, Abstract 4698: Immuno-oncological efficacy of RXDX-106, a novel, selective and potent small molecule TAM (TYRO3, AXL, MER) inhibitor
Journal Articles

Abstract 4191: RXDX-106, a novel, selective and potent small molecule TAM (TYRO3, AXL, MER) inhibitor, demonstrates efficacy in TAM-driven tumors

Erin D. Lew, Elizabeth A. Tindall, Joanne Oh, Colin Walsh, Maria Barrera, Heather Ely, Amy Diliberto, Yumi Yokoyama, Gary Li, Amanda Albert
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 4191.
https://doi.org/10.1158/1538-7445.AM2017-4191
Published: 01 July 2017
View article titled, Abstract 4191: RXDX-106, a novel, selective and potent small molecule TAM (TYRO3, AXL, MER) inhibitor, demonstrates efficacy in TAM-driven tumors
Journal Articles

Abstract LB-080: Imprime PGG, a β-glucan PAMP (pathogen-associated molecular pattern) activates the direct killing functions of innate immune cells in concert with tumor targeting antibodies

Steven M. Leonardo, Ross B. Fulton, Keith B. Gorden, Katy Fraser, Ben Harrison, Takashi Kangas, Adria Jonas, Yumi Yokoyama, Nadine Ottoson, Nandita Bose, Jeremy R. Graff
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): LB-080.
https://doi.org/10.1158/1538-7445.AM2016-LB-080
Published: 15 July 2016
View article titled, Abstract LB-080: Imprime PGG, a β-glucan PAMP (pathogen-associated molecular pattern) activates the direct killing functions of innate immune cells in concert with tumor targeting antibodies
Journal Articles

Abstract B65: Immune cell priming and potentiation of anti-tumor effects by Imprime PGG®

Yumi Yokoyama, Mariana I. Nelson, Nadine C. Ottoson, Mark N. Kirstein, Richard Walsh, Kyle S. Michel, Michael E. Danielson, Mary A. Antonysamy
Journal: Cancer Research
Cancer Res (2013) 73 (19_Supplement): B65.
https://doi.org/10.1158/1538-7445.FBCR13-B65
Published: 15 May 2014
View article titled, Abstract B65: Immune cell priming and potentiation of anti-tumor effects by Imprime PGG®
Journal Articles

Abstract A19: Imprime PGG®, a soluble β-1,3/1,6 immunomodulatory glucan, induces enhanced antitumor activity in an in vivo pancreatic tumor model when combined with cetuximab and gemcitabine.

Mary A. Antonysamy, Yumi Yokoyama, Arkadiusz Z. Dudek, Nadine Ottoson, William Grossman
Journal: Cancer Research
Cancer Res (2012) 72 (14_Supplement): A19.
https://doi.org/10.1158/1538-7445.PANCA2012-A19
Published: 03 April 2014
View article titled, Abstract A19: Imprime PGG<sup>®</sup>, a soluble β-1,3/1,6 immunomodulatory glucan, induces enhanced antitumor activity in an in vivo pancreatic tumor model when combined with cetuximab and gemcitabine.
Journal Articles

Abstract #865: Characterization of mouse pancreatic cancer cells from KrasG12D/p53-/-, KrasG12D/Smad4-/- transgenic mice, and differential effect of triptolide on the tumor growth

Yumi Yokoyama, Daniel Borja-Cacho, Christopher Klug, Selwyn V, Ashok Saluja
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 865.
Published: 01 May 2009
View article titled, Abstract #865: Characterization of mouse pancreatic cancer cells from Kras<sup>G12D/</sup>p53<sup>-/-</sup>, Kras<sup>G12D/</sup>Smad4<sup>-/- </sup>transgenic mice, and differential effect of triptolide on the tumor growth
Journal Articles

Mouse pancreatic cancer cells from KrasG12D/p53-/- transgenic mice overexpress Heat shock protein 70 (HSP70), and its inhibition by triptolide decreases cell viability.

Yumi Yokoyama, Vikas Dudeja, Rajinder Dawra, Daniel Borja-Cacho, Paul Zwolak, Rupjyoti Talukdar, Rohit Chugh, Christopher Klug, Selwyn Vickers, Ashok Saluja
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): LB-190.
Published: 01 May 2008
View article titled, Mouse pancreatic cancer cells from Kras<sup>G12D/p53-/- </sup>transgenic mice overexpress Heat shock protein 70 (HSP70), and its inhibition by triptolide decreases cell viability.
Journal Articles

Endostatin Binding to Ovarian Cancer Cells Inhibits Peritoneal Attachment and Dissemination

Yumi Yokoyama, Gerald Sedgewick, S. Ramakrishnan
Journal: Cancer Research
Cancer Res (2007) 67 (22): 10813–10822.
https://doi.org/10.1158/0008-5472.CAN-07-0172
Published: 15 November 2007
View article titled, Endostatin Binding to Ovarian Cancer Cells Inhibits Peritoneal Attachment and Dissemination
Open the PDF for Endostatin Binding to Ovarian Cancer Cells Inhibits Peritoneal Attachment and Dissemination in another window
Includes: Supplementary data
Journal Articles

A novel, early effect of endostatin - Inhibition of vessel cooption and peritoneal dissemination of ovarian cancer cells

Yumi Yokoyama, Jerry Sedgewick, S. Ramakrishnan
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 1093–1094.
Published: 01 May 2005
View article titled, A novel, early effect of endostatin - Inhibition of vessel cooption and peritoneal dissemination of ovarian cancer cells
Journal Articles

The Designed Angiostatic Peptide Anginex Synergistically Improves Chemotherapy and Antiangiogenesis Therapy with Angiostatin

Ruud P. M. Dings, Yumi Yokoyama, Sundaram Ramakrishnan, Arjan W. Griffioen, Kevin H. Mayo
Journal: Cancer Research
Cancer Res (2003) 63 (2): 382–385.
Published: 15 January 2003
View article titled, The Designed Angiostatic Peptide Anginex Synergistically Improves Chemotherapy and Antiangiogenesis Therapy with Angiostatin
Open the PDF for The Designed Angiostatic Peptide Anginex Synergistically Improves Chemotherapy and Antiangiogenesis Therapy with Angiostatin in another window
Journal Articles

Effect of Endostatin on Spontaneous Tumorigenesis of Mammary Adenocarcinomas in a Transgenic Mouse Model

Yumi Yokoyama, Jeffrey E. Green, Vikas P. Sukhatme, S. Ramakrishnan
Journal: Cancer Research
Cancer Res (2000) 60 (16): 4362–4365.
Published: 01 August 2000
View article titled, Effect of Endostatin on Spontaneous Tumorigenesis of Mammary Adenocarcinomas in a Transgenic Mouse Model
Open the PDF for Effect of Endostatin on Spontaneous Tumorigenesis of Mammary Adenocarcinomas in a Transgenic Mouse Model in another window